Goldie Taylor, Senior Vice President, Chief Communications and Marketing Officer, has been named to Ragan’s Top Women in Communications, Class of 2026, recognized in the Healthcare Communicators category. Please join us in congratulating her on this recognition. View the full list: bit.ly/4b2jyyL

Becker’s Hospital Review reports that a noninvasive AI tool developed by @danafarber.bsky.social’s Benjamin Kann, MD, improved clinical risk stratification when integrated into existing prognostic frameworks for patients with oropharyngeal carcinoma. Read more at bit.ly/3KSFamV

Benjamin Ebert, MD, PhD, President and CEO of @danafarber.bsky.social, shared his perspectives with Boston Business Journal on the institute’s planned investments in AI research and rare disease drug development while keeping plans for its new hospital on track in the new year. bit.ly/3MRd5gp

How much has cancer care changed in the first quarter of this century? Quite a lot, thanks to cancer research here and around the world. Get the details here: bit.ly/4pJ9Ju9

Every year, physician researchers at Dana-Farber reveal new treatments, protocols, and outcomes that advance cancer research. Here are three of the most exciting — several nearing FDA approval. Read more: bit.ly/48uatxg

“It feels really fulfilling and affirming, and it truly is an honor,” @danafarber.bsky.social’s Alexandria Monteiro tells @boston25news.com while donating her stem cells at the Kraft Family Blood Donor Center during the holidays to a pediatric patient needing a transplant. ➡️ bit.ly/49fDX0X

“Now, for the first time ever, we’ve created a molecularly based stratification biomarker,” says pediatric oncologist Brian Crompton, MD. The STAG2 biomarker may open the door to finding more effective treatments for Ewing sarcoma. Learn more: bit.ly/44Q2zvO

We’re proud to be included in Becker’s Great Hospitals in America list, which recognizes organizations that stand out for exceptional clinical performance, unwavering focus on patient safety, and dedication to innovation, research and education. View the full list here: bit.ly/49nr2Lv

The COMET study led by Ann Partridge, MD, MPH, and colleagues was recognized by @jama.com as part of their "Research of the Year” roundup. Results of COMET results suggest that active monitoring could be a reasonable approach to management of low-risk DCIS. Learn more: bit.ly/492IwLS

The FDA has approved trastuzumab deruxtecan (T-DXd) in combination with pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. The approval is based on results from the phase III DESTINY-Breast09 study, led by Sara Tolaney, MD, Chief of Breast Oncology.

We’re thrilled that both our adult and pediatric stem cell/bone marrow transplant programs earned the highest possible +1 score in the 2025 CIBMTR Survival Report — exceeding expected 1-year survival nationwide. Thank you to our dedicated team and partners for advancing patient care every day.

ICYMI: Breast cancer research breakthroughs discussed at #ESMO25 by @danafarber.bsky.social's Breast Oncology Center. Learn how these discoveries will impact clinical care going forward: 🎥 bit.ly/4j4fa4x

Meet Evan Chen, MD, a medical oncologist who treats patients with acute leukemias and myeloid malignancies. Learn more about his clinic research, which focuses on the development of cellular therapies for leukemias and translational studies of leukemia epigenetics: bit.ly/48ZI6rp

"This gift keeps reinforcing to me the beauty in the world,” @danafarber.bsky.social oncology nurse navigator Idalina Colburn tells @wbztv.bsky.social’s Anna Meiler after Good News Movement surprised her with a trip from Expedia so her family may continue making happy memories. ➡️ bit.ly/4oUGbIX

Congratulations to Robert Soiffer, MD, the 2025 recipient of the Edward J. Benz Award for Advancing the Careers of Dana-Farber Faculty. This annual award recognizes a faculty member who goes above and beyond to advance the careers of fellow faculty.

Melissa Levin, MSW, LICSW, recently talked with @ascopost.bsky.social about our Neuro-Inclusive Oncology Care and Empowerment Program. Learn more: bit.ly/4rPKRCJ

We’re proud to be included in @forbes.com’s Top 2025 Charities list! Thank you for your continued support and generosity as we advance our momentum of discovery to improve cancer care and expand access in our community and for patients around the world. View the full list: bit.ly/4rS4E47

Congratulations to @stolaney1.bsky.social on receiving @theaacr.bsky.social's Outstanding Investigator Award for Breast Cancer Research. As part of this recognition, she will present her lecture “Lessons Learned: A Journey Towards Treatment Personalization” tomorrow at #SABCS25. ➡️ bit.ly/3KouH2i

Congratulations to Nolan Priedigkeit, MD, PhD, on receiving the 2025 @sabcs.bsky.social Rising Star Award, which recognizes early career scientists and clinicians conducting impactful research in the field of breast cancer.

Improvements in immunotherapy are leading to favorable results and reduced toxicities in treating patients with acute lymphoblastic leukemia. Get up to speed on the latest with Marlise R. Luskin, MD, MSCE: bit.ly/3JhTFQo

We're proud to showcase our contributions to breast cancer research at #SABCS25. For highlights, schedules, and more, visit us at bit.ly/3Y3DGJe#SABCS25

Johann-Christoph Jann, MD, presents new research on the activation of endogenous retroviral elements that may drive inflammation and cellular transformation in STAG2-mutant myeloid malignancies. @tothovalab.bsky.social #ASH25

We’re back today at #ASH25. Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in blood cancer care and research or join us at our upcoming discussions and poster presentations: bit.ly/3LYDHeL

The second day of poster presentations at #ASH25 featured research ranging from venetoclax and pirtobrutinib in relapsed/refractory Waldenström's macroglobulinemia to spatial proteomics of the bone marrow.

Andrew Lane, MD, PhD, shares an update on TAG-AZA-VEN for BPDCN. “These early results point to a safer, more workable option that can keep patients on track, often toward transplant, while addressing co-existing disease.” #ASH25

Austin Kim, MD, presents results from the phase 1/2 MAVO study evaluating acalabrutinib + venetoclax + obinutuzumab in patients with relapsed/refractory and previously untreated mantle cell lymphoma. #ASH25

Marlise Luskin, MD, MSCE, shares phase 1 data on venetoclax + inotuzumab ozogamicin in relapsed/refractory ALL. #ASH25

Jennifer Brown, MD, PhD, reports on insights from the ALPINE trial on symptom-based progression-free survival (S-PFS) as a patient-centric endpoint in CLL/SLL. The approach helps differentiate treatments and strengthens patient-focused evaluation in future trials. #ASH25

Shayna Sarosiek, MD, reports new data from the WM-NET1 trial evaluating loncastuximab tesirine in relapsed/refractory Waldenström macroglobulinemia, including high-risk patients with CXCR4 or TP53 mutations — a group known to have more therapy-resistant disease and shorter response durations. #ASH25

"Rituximab & epcoritamab has shown impressive activity and manageable safety profile. We need longer follow-up to determine durability of responses, but R+Epcor could represent an attractive chemotherapy/ lenalidomide-free frontline treatment options for patients with FL." - Reid Merryman, MD #ASH25

#ASH25 continues today! Follow along here and with @danafarbernews.bsky.social as we learn about and explore the latest in blood cancer care and research, or join us live at our upcoming discussions and poster presentations: bit.ly/3LYDHeL

The first day of poster presentations at #ASH25 featured research ranging from immune cell dynamics to epcoritamab in primary cells.

Stella Jaeckle reflects on the molecular and functional determinants of response to venetoclax and inotuzumab ozogamicin in CD22-positive ALL. #ASH25

Sabine Allam, MD, reports on results from the PROMISE Study, which screened ~30,000 individuals for monoclonal gammopathies. #ASH25

@nicogagelmann.bsky.social shares findings that longer telomeres in donors ≥35 are associated with reduced graft failure and lower non-relapse mortality following allogeneic HCT. #ASH25

Anna Clara Bader is discussing LIME (Live Immune Modulating Engagers) — a first-in-class platform for immunotherapy. Early data suggests this approach may help enhance targeting and efficacy while reducing toxicities, including risks like cytokine release syndrome. #ASH25

Rizwan Romee, MD, highlights new insights on the characterization of infused bhv-1100 armored memory-like NK cells in MRD+ multiple myeloma following autologous stem cell transplant. #ASH25

Jorge Castillo, MD, shares data on an all-oral, non-chemo, fixed-duration regimen for Waldenström macroglobulinemia using pirtobrutinib and venetoclax. The combination delivered rapid, profound and 100% overall responses with manageable side effects and high rate of deep responses. #ASH25

Steven P. Treon, MD, PhD, shares findings showing that double-hit TP53 alterations define an ultra–high-risk subset of previously treated, MYD88-mutated Waldenström macroglobulinemia. #ASH25

Lachelle Weeks, MD, PhD, shares findings that demonstrate sickle cell disease may predispose patients to high-risk clonal hematopoiesis. This multinational cohort defined CH prevalence, age distribution, and mutational profiles in SCD relative to non‐SCD controls and other hemoglobinopathies. #ASH25

Inhye Ahn, MD, reports on a phase 1 study of BGB-16673 in relapsed or refractory CLL with an overall response rate of 86%. Responses were observed across various patient subgroups, including patients with BTK mutations which are associated with resistance to conventional kinase inhibitors. #ASH25

We’re excited to be at #ASH25! Follow along here and with @danafarbernews.bsky.social as we learn about and explore the latest in blood cancer care and research, or join us live at our upcoming discussions and poster presentations: bit.ly/3LYDHeL

@sabcs.bsky.social kicks off next week and we're proud to highlight several exciting abstracts being presented by our breast oncology faculty. Check out the highlights here: bit.ly/3Ksfuxa #SABCS25

Andrew Lane, MD, PhD, is exploring next-generation CD123 targeted therapies across acute myeloid leukemia, BPDCN, and other blood cancers. Dive into the physician-focused review here: bit.ly/3JvnCMT

Show your support for @danafarber.bsky.social and the Jimmy Fund! Your donation today on GivingTuesday will be TRIPLED by Arbella Insurance Group to make 3X the impact AND you will receive a limited-edition Dana-Farber baseball hat. Donate today: jimmyfund.gives/hk3hfu5u.

Today is #GivingTuesday! Your support will help fuel the next lifesaving treatment, research discovery, and victory over cancer for patients like Capri and their families. Make 3X the impact when you donate today: dana-farber.gives/GivingTuesday#GivingTuesday

Our researchers are presenting more than 120 studies at #ASH25, covering everything from sickle cell disease and Waldenström’s to Follicular and Mantle Cell Lymphomas and MDS. View the highlights: bit.ly/4akDLiW

Congratulations to Richard Stone, MD, who has been named the 2025 recipient of the Richard L. Schilsky Cancer and Leukemia Group B Achievement Award by the Alliance for Clinical Trials in Oncology Foundation.

Jacqueline Garcia, MD, is exploring ongoing clinical research to test novel triplet therapies for safety and efficacy with a precision medicine approach for patients with acute myeloid leukemia. Explore the latest updates: bit.ly/3LmZEUC

Please join us in congratulating Christopher Lathan, MD, MS, MPH, as the recipient of this year's Arthur T. Skarin Award on behalf of the Board of Directors of the Massachusetts Society of Clinical Oncologists (MSCO).